Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$20.05 USD
+0.07 (0.35%)
Updated Jul 26, 2024 03:55 PM ET
After-Market: $20.04 -0.01 (-0.05%) 4:10 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
PCRX 20.05 +0.07(0.35%)
Will PCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
Other News for PCRX
Expert Ratings For Pacira BioSciences
First Week of September 20th Options Trading For Pacira BioSciences (PCRX)
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025